Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04683315 · ClinicalTrials.gov registry record · Phase 2
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
A Phase 2 study of Pancreatic Cancer, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 2
- Study locations
NCT04683315: Recruiting Phase 2 study of Pancreatic Cancer, sponsored by Medical College of Wisconsin.
NCT04683315 is a Phase 2 study of Pancreatic Cancer that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 84 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04683315, a Phase 2 study of Pancreatic Cancer, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
Primary Outcome
The number of subjects who receive PurIST classification-directed therapy and have a treatment response following 12 weeks of therapy.
Conditions Studied
Interventions
- DRUG mFOLFIRINOX Treatment Regimen
- DRUG Gemcitabine/Nab-paclitaxel Treatment Regimen
Study Locations (2)
Arizona
- HonorHealth Medical Group - Scottsdale
Wisconsin
- Froedtert & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT04683315 shows while recruiting
NCT04683315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which mFOLFIRINOX Treatment Regimen is the first listed.
NCT04683315 reports a single indexed study location in Arizona, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04683315 about?
NCT04683315 is a clinical study titled "PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples". This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
What is the current status of trial NCT04683315?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2021-04-01. Estimated completion is 2028-12-31.
What conditions does trial NCT04683315 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT04683315?
The interventions under investigation include: mFOLFIRINOX Treatment Regimen (DRUG), Gemcitabine/Nab-paclitaxel Treatment Regimen (DRUG).
Who is sponsoring clinical trial NCT04683315?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04683315 being conducted?
This trial has 2 study locations across Arizona, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04683315's enrollment target sits among peer trials
84 117th of 278 higher than 160 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI